You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 11, 2025

Details for New Drug Application (NDA): 020500

✉ Email this page to a colleague

NDA 020500 describes MEPRON, which is a drug marketed by Glaxosmithkline Llc and is included in two NDAs. It is available from one supplier. Additional details are available on the MEPRON profile page.

The generic ingredient in MEPRON is atovaquone. There are sixteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the atovaquone profile page.

Summary for 020500

Tradename:	MEPRON
Applicant:	Glaxosmithkline Llc
Ingredient:	atovaquone
Patents:	0

Pharmacology for NDA: 020500

Medical Subject Heading (MeSH) Categories for 020500

Anti-Infective Agents
Antimalarials
Enzyme Inhibitors

Suppliers and Packaging for NDA: 020500

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
MEPRON	atovaquone	SUSPENSION;ORAL	020500	NDA	GlaxoSmithKline LLC	0173-0547	0173-0547-00	42 POUCH in 1 DOSE PACK (0173-0547-00) / 5 mL in 1 POUCH
MEPRON	atovaquone	SUSPENSION;ORAL	020500	NDA	GlaxoSmithKline LLC	0173-0665	0173-0665-18	210 mL in 1 BOTTLE (0173-0665-18)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SUSPENSION;ORAL			Strength	750MG/5ML
Approval Date:	Feb 8, 1995	TE:	AB	RLD:	Yes

Expired US Patents for NDA 020500

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Llc	MEPRON	atovaquone	SUSPENSION;ORAL	020500-001	Feb 8, 1995	4,981,874*PED	⤷ Get Started Free
Glaxosmithkline Llc	MEPRON	atovaquone	SUSPENSION;ORAL	020500-001	Feb 8, 1995	6,649,659*PED	⤷ Get Started Free
Glaxosmithkline Llc	MEPRON	atovaquone	SUSPENSION;ORAL	020500-001	Feb 8, 1995	5,053,432*PED	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.